Intercept Pharma

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Intercept Pharma reports robust earnings, eyes growth amid competitive challenges

Intercept Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic advancements, and a focus on innovation and market expansion.
The company's achievements in sales growth, patent protection, and financial stability position it well for future growth and leadership in the PBC and NASH markets.
Challenges in competitive dynamics and regulatory landscape require proactive strategies, while opportunities in new programs and market developments offer avenues for continued success.
Overall, Intercept Pharma's performance underscores a resilient and forward-thinking approach to navigating the complexities of the pharmaceutical industry and driving sustainable growth.

Intercept Pharma reports growth in sales and navigates NASH landscape

Intercept Pharma's Q1 2023 performance saw growth in net sales and strong sales performance of OCALIVA.
The company's focus on F3-like NASH patients and competitive positioning of OCA are key strengths.
Challenges include pricing strategy discussions and questions on combination approaches.
Opportunities lie in addressing AdCom discussions, expanding prescriber base, and preventing cirrhosis progression.

Intercept Pharma reports strong Q2 earnings, eyes FDA relations

Intercept Pharma's strong performance in Q2 2023 shows progress towards profitability by 2024. The company is addressing challenges in FDA relations and study enrollments while leveraging market opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases.

Intercept Pharmaceuticals' experimental NASH treatment failed in patients with liver cirrhosis, leading ICPT stock to plummet Friday. The post Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients appeared first on Investor's Business Daily.

Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients

Today is a big day for Intercept Pharmaceuticals (NASDAQ: ICPT ). The company just announced the clinical-trial results of Intercept's treatment for NASH cirrhosis.

Why Is Intercept Pharmaceuticals (ICPT) Stock Down 20% Today?

Rent-A-Center

Poor earnings and a business setback were costly for these companies.

Nike's Down, but These 2 Nasdaq Stocks Fell Even Further Friday

Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study Company remains on track to resubmit new drug application (NDA) for OCA in its lead indication of fibrosis due to NASH by year end based on its positive Phase 3 REGENERATE study

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint

Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.

Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why

Source: Postmodern Studio / Shutterstock Intercept Pharmaceuticals (NASDAQ: ICPT ) stock is on the move Wednesday after giving investors an update on how it improved its financials. A press release from the biopharmaceutical company covers several recent transactions.

Why Is Intercept Pharmaceuticals (ICPT) Stock Up Today?

Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million

Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning

Combined clinical trial and real-world data with six years of follow-up provides important evidence of efficacy

Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Why Is Intercept (ICPT) Up 15.4% Since Last Earnings Report?

MORRISTOWN, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered into privately negotiated agreements to repurchase $327.9 million of its secured convertible debt using a combination of cash and equity. The repurchase is expected to close promptly, subject to and following customary closing conditions.

Intercept Pharmaceuticals Announces Repurchase of Convertible Notes

Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.

Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva

MORRISTOWN, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the management team of Intercept will participate in B. Riley's PBC (Primary Biliary Cholangitis) Mini Symposium: Orphan Liver Disease That May Not Be As Rare As You'd Think. This PBC-focused event will take place virtually on Wednesday, August 24.

Intercept Pharmaceuticals to Participate in B. Riley's PBC Symposium on August 24, 2022

Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised)

Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.

Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)

Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.

Intercept (ICPT) Earnings and Sales Miss Estimates in Q2

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q2 2022 Results Conference Call August 2, 2022 8:30 AM ET Company Participants Nareg Sagherian - ED, IR Jerry Durso - President and CEO Linda Richardson - Chief Commercial Officer Dr. Michelle Berrey - President of Research & Development and Chief Medical Officer Andrew Saik - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler Kelechi Chikere - Jefferies Steve Seedhouse - Raymond James Thomas Smith - SVB Securities Jon Wolleben - JMP Securities Mayank Mamtani - B. Riley Securities Ellie Merle - UBS Matt Dellatorre - Goldman Sachs Operator Hello.

Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q2 2022 Results - Earnings Call Transcript

Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Misses Revenue Estimates

MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2022 financial results prior to market open on Wednesday, August 3, 2022. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022

Altimmune

Amylyx Pharmaceuticals

Arcutis Biotherapeutics

Axsome Therapeutics

bluebird bio

Heron Therapeutics

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. The post 7 Biotech Stocks to Buy for Q3 appeared first on InvestorPlace.

7 Biotech Stocks to Buy for Q3

Yesterday, Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced data from the new interim analysis of the Phase 3 REGENERATE trial evaluating obeticholic acid in nonalcoholic steatohepatitis (NASH). Needham writes that the efficacy results were similar to the initial results.

Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path

Intercept (ICPT) reports positive top-line results from a new analysis of its ongoing pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.

Intercept (ICPT) Reports Positive Data From NASH Study on OCA

Intercept (ICPT) currently has only one marketed product in its portfolio, Ocaliva, for treating PBC. The company continues to evaluate the potential of OCA in treating progressive liver diseases.

Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt

A fresh press release from Intercept Pharmaceuticals reveals positive data from an important clinical trial. Yet, ICPT stock is dropping.

Why Did Intercept Pharmaceuticals (ICPT) Stock Fall 10% Today?

MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept and Advanz Pharma announced on May 5, 2022, has now closed. As a result of this transaction, Intercept's international business has been divested and its international commercial and medical infrastructure have transitioned to Advanz Pharma.

Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.

MORRISTOWN, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts highlighting the benefits of obeticholic acid (OCA) in individuals with primary biliary cholangitis (PBC) will be presented at the International Liver Congress™ 2022, the 57th Annual Meeting of the European Association for the Study of the Liver (EASL), to be held in London from June 22 to June 26, 2022.

News for Intercept Pharma Stock (ICPT)